{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG000","lowerLimit":"302","upperLimit":"NA","value":"NA"},{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG001","lowerLimit":"583","upperLimit":"NA","value":"NA"},{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Not estimable based on the Kaplan-Meier method because of insufficient follow up time","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"17"}],"units":"Participants"}],"description":"Duration of response is the time from date of first documented confirmed response to date of first documented progressive disease. A confirmed response is a response that has been observed on at least two consecutive assessments.\n\nDisease progression requires any one or more of the following: serum m-protein increase \\>= 25% from nadir(absolute increase \\>= 0.5 g/dL); Urine m-protein increase \\>= 25% from nadir(absolute increase \\>= 200 mg/24 hr), bone marrow plasma cell percentage increase \\>= 25% from nadir(absolute increase \\>= 10%), new bone lesion or soft tissue plasmacytomas.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally \\[PO\\] on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 25 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG000","title":"V-DR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.\n\nLenalidomide: 15 mg PO on Days 1 through 14 of a 3-week cycle for 8 cycles, then stop.","id":"OG001","title":"VDCR"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg orally PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1 and 8 of a 3-week cycle for 8 cycles, then stop.","id":"OG002","title":"V-DC"},{"description":"Bortezomib: 1.3 mg/m\\^2/dose IV on Days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on Days 1, 8, 15, and 22 of a 6-week cycle for 4 cycles.\n\nDexamethasone: 40 mg PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.\n\nCyclophosphamide: 500 mg/m\\^2 dose PO on Days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop.","id":"OG003","title":"VDC-mod"}],"paramType":"MEDIAN","populationDescription":"Responders (patients achieved complete and partial response) in the response evaluable population.","reportingStatus":"POSTED","timeFrame":"Up to 48 weeks or until disease progression","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"days"}